Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 3/20 | 0.38 |
| ▸ | PPARA | Q07869 | 3/20 | 0.38 |
| ▸ | FABP3 | P05413 | 2/20 | 0.37 |
| ▸ | SNCA | P37840 | 1/20 | 0.37 |
| ▸ | FABP4 | P15090 | 2/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5119989 | 0.90 | PPARG (0.56) | PPARGLIPE | |
| SCHEMBL5120850 | 0.90 | PPARG (0.47) | PPARGL3MBTL1LIPEPPARDPPARA | |
| SCHEMBL5120546 | 0.88 | PPARG (0.55) | PPARGLIPE | |
| SCHEMBL5105830 | 0.87 | PPARG (0.52) | PPARGPPARDPPARAFABP3FABP4 | |
| SCHEMBL5120724 | 0.82 | PPARG (0.42) | PPARGLIPEPPARDPPARA | |
| SCHEMBL5120057 | 0.81 | PPARG (0.51) | PPARGPPARDPPARAFABP3SNCA | |
| SCHEMBL5121618 | 0.81 | PPARG (0.60) | PPARG | |
| SCHEMBL5113591 | 0.80 | PPARG (0.55) | PPARGLIPE | |
| SCHEMBL5120220 | 0.80 | PPARG (0.58) | PPARG | |
| SCHEMBL5113212 | 0.80 | PPARG (0.57) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | PPARG 52/4885L3MBTL1 2694/4885LIPE 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.